Xencor Inc
Xencor IncProfile last edited on: 4/10/2018
111 West Lemon AvenueMonrovia, CA 91016
|
Business Identifier: Redesigning antibody drugs: engineered mAbs for autoimmune diseases, asthma, allergic diseases, and cancer
Public Profile:
Xencor Inc is a clinical-stage biopharmaceutical company organized around expanding the therapeutic boundaries of monoclonal antibody drugs. Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases. 11 programs are in clinical testing and many more are in preclinical development.. Using a proprietary XmAb technology platform the firm is creating next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. In contrast to conventional approaches to antibody design, which focus on the portion of antibodies that interact with target antigens, Xencor is focused on the portion of the antibody that interacts with multiple segments of the immune system. This portion, referred to as the Fc domain, is constant and interchangeable among antibodies. The firm’s engineered Fc domains, the XmAb technology, can be readily substituted for natural Fc domains potentially enhancing antibody performance by, for example, increasing immune inhibitory activity, improving cytotoxicity or extending circulating half-life, while typically maintaining over 99.5% identity in structure and sequence to natural antibodies. By improving over natural antibody function, management believe that the firm’s XmAb-engineered antibodies offer innovative approaches to treating disease and potential clinical advantages over other treatments.
Xencor Inc is a clinical-stage biopharmaceutical company organized around expanding the therapeutic boundaries of monoclonal antibody drugs. Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases. 11 programs are in clinical testing and many more are in preclinical development.. Using a proprietary XmAb technology platform the firm is creating next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. In contrast to conventional approaches to antibody design, which focus on the portion of antibodies that interact with target antigens, Xencor is focused on the portion of the antibody that interacts with multiple segments of the immune system. This portion, referred to as the Fc domain, is constant and interchangeable among antibodies. The firm’s engineered Fc domains, the XmAb technology, can be readily substituted for natural Fc domains potentially enhancing antibody performance by, for example, increasing immune inhibitory activity, improving cytotoxicity or extending circulating half-life, while typically maintaining over 99.5% identity in structure and sequence to natural antibodies. By improving over natural antibody function, management believe that the firm’s XmAb-engineered antibodies offer innovative approaches to treating disease and potential clinical advantages over other treatments.
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Unlock access
To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account
To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account Smart Office Options
|
|
SBIR firms in the news
WikiProfile
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Processing...